Escient Pharmaceuticals develops first-in-class oral therapeutics targeting Mas-related G protein-coupled receptors (MRGPRs) to treat neurosensory-inflammatory disorders such as chronic urticaria and cholestatic pruritus. Their approach utilizes small molecule antagonists to address the underlying mechanisms of neurogenic inflammation, providing potential new treatment options for patients with limited existing therapies.
Funding
$120M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many neurosensory-inflammatory disorders, such as chronic urticaria and cholestatic pruritus, have limited effective treatments, leaving patients with unmet needs. Current therapies often fail to address the underlying mechanisms of neurogenic inflammation, resulting in inadequate symptom control.
Solution
Escient Pharmaceuticals develops oral therapeutics targeting Mas-related G protein-coupled receptors (MRGPRs) to treat neurosensory-inflammatory disorders. Their approach utilizes small molecule antagonists to modulate the neurosensory-inflammatory axis, offering potential new treatment options. The company's product candidates are designed to address a range of disorders involving neurogenic inflammation, including chronic urticaria, atopic dermatitis, asthma, and severe forms of pruritus.
Target Audience
The primary target audience includes patients suffering from neurosensory-inflammatory disorders such as chronic urticaria, cholestatic pruritus, atopic dermatitis, and asthma, as well as the physicians who treat them.
Features
- EP262: An MRGPRX2 antagonist being evaluated in chronic urticaria and other mast cell mediated disorders.
- EP547: An MRGPRX4 antagonist being evaluated in cholestatic pruritus.
- Targeted small molecule therapeutics designed to modulate the neurosensory-inflammatory axis.
- Oral administration for patient convenience.
- First-in-class therapeutics targeting novel pathways.